Clinical data
ATC code none
CAS Number 537034-22-3 YesY
PubChem (CID) 23649599
ChemSpider 26519428
Chemical and physical data
Formula C31H35Cl2F6N3O3
Molar mass 682.524 g/mol
3D model (Jmol) Interactive image

Burapitant (SSR-240,600) is a drug developed by Sanofi-Aventis which was one of the first compounds developed that acts as a potent and selective antagonist for the NK1 receptor.[1][2][3] While burapitant itself did not proceed beyond early clinical trials and was never developed for clinical use in humans, promising animal results from this and related compounds have led to a number of novel drugs from this class that have now been introduced into medical use.


  1. Emonds-Alt X, Proietto V, Steinberg R, Oury-Donat F, Vigé X, Vilain P, Naline E, Daoui S, Advenier C, Le Fur G, Maffrand JP, Soubrié P, Pascal M. SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization. J Pharmacol Exp Ther. 2002 Dec;303(3):1171-9. PMID 12438541
  2. Steinberg R, Alonso R, Rouquier L, Desvignes C, Michaud JC, Cudennec A, Jung M, Simiand J, Griebel G, Emonds-Alt X, Le Fur G, Soubrié P. SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]-4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin 1 receptor: II. Neurochemical and behavioral characterization. J Pharmacol Exp Ther. 2002 Dec;303(3):1180-8. PMID 12438542
  3. Pérez S, Tierney A, Deniau JM, Kemel ML. Tachykinin regulation of cholinergic transmission in the limbic/prefrontal territory of the rat dorsal striatum: implication of new neurokinine 1-sensitive receptor binding site and interaction with enkephalin/mu opioid receptor transmission. J Neurochem. 2007 Dec;103(6):2153-63. PMID 17949415

This article is issued from Wikipedia - version of the 9/19/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.